HRP20171620T1 - N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol - Google Patents
N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol Download PDFInfo
- Publication number
- HRP20171620T1 HRP20171620T1 HRP20171620TT HRP20171620T HRP20171620T1 HR P20171620 T1 HRP20171620 T1 HR P20171620T1 HR P20171620T T HRP20171620T T HR P20171620TT HR P20171620 T HRP20171620 T HR P20171620T HR P20171620 T1 HRP20171620 T1 HR P20171620T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- hemisulfate salt
- degrees
- specified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (10)
1. Hemisulfatna sol spoja (I):
[image]
2. Hemisulfatna sol spoja (I) prema patentnom zahtjevu 1, gdje je navedena sol spoja (I) kristalna.
3. Hemisulfatna sol spoja (I) prema patentnom zahtjevu 1, gdje navedena sol spoja (I) je seskvihidrat.
4. Hemisulfatna sol spoja (I) prema patentnom zahtjevu 3, gdje je navedena sol kristalni oblik H1.5-1 karakteriziran sljedećim:
Parametri jedinice stanice su jednaki sljedećem:
Dimenzije stanice:
a = 0.92 Å
b = 33.04 Å
c = 7.90 Å
α = 90 stupnjeva
β = 90 stupnjeva
γ = 90 stupnjeva
Prostorna grupa: P21212
Molekula spoja (I)/asimetrična jedinica: 1
Zapremina = 2851 Å3
Gustoća (izračunato) = 1.423 g/cm3,
gdje je mjerenje navedenog kristalnog oblika na temperaturi od oko 25°C.
5. Hemisulfatna sol spoja (I) prema patentnom zahtjevu 4, gdje navedeni oblik H1.5-1 je karakteriziran jednim ili više od sljedećeg:
a) uzorak difrakcije x-zraka praškaste supstance (CuKα λ=1.5418Å) koji sadrži 2θ vrijednosti: 5.4±0.1, 8.6±0.1, 9.7±0.1, 12.4±0.1, 14.9±0.1,17.6±0.1, 18.1±0.1, 20.5±0.1, 21.4±0.1, i 22.0±0.1, gdje je mjerenje kristalnog oblika na temperaturi od oko 25°C;
i/ili
b) spektri nuklearne rezonance u čvrstom stanju koji sadrže šest ili više vrhova(δ (ppm) u odnosu na TMS) koji su odabrani od: 26.6±0.1, 27.1±0.1, 28.3±0.1, 30.7±0.1, 43,1±0.1, 45.9±0.1, 47.1±0.1, 52.0±0.1, 54.2±0.1, 72.5±0.1, 117.0±0.1, 117.7±0.1, 124.2±0.1, 125.2±0.1, 128.3±0.1, 130.3±0.1, 131.4±0.1, 134.1±0.1, 140.8±0.1, 144.7±0.1, 148.7±0.1, 149.8±0.1, 151.2±0.1, 153.4±0.1, 155,1±0.1, 155.6±0.1 i 156.7±0.1.
6. Farmaceutska kompozicija koja sadrži navedenu hemisulfatnu sol spoja (I) prema patentnom zahtjevu 1; i farmaceutski prihvatljiv nosač ili razblaživač.
7. Farmaceutska kompozicija prema patentnom zahtjevu 6, gdje je navedena hemisulfatna sol spoja (I) seskvihidrat.
8. Farmaceutska kompozicija prema patentnom zahtjevu 7, gdje je navedena hemisulfatna sol spoja (I) kristalni oblik H1.5-1 karakteriziran sljedećim:
Parametri jedinice stanice su jednaki sljedećem:
Dimenzije stanice:
a = 10.92 Å
b = 33.04 Å
c = 7.90 Å
α = 90 stupnjeva
β = 90 stupnjeva
γ = 90 stupnjeva
Prostorna grupa: P21212
Molekule spoja (I)/asimetrična jedinica: 1
Zapremina = 2851 Å3
Gustoća (računato) = 1.423 g/cm3,
gdje je mjerenje navedenog kristalnog oblika na temperaturi od oko 25 °C.
9. Hemisulfatna sol spoja (I) prema bilo kojem patentnom zahtjevu 1 do 5 se koristi kao lijek.
10. Hemisulfatna sol spoja (I) prema bilo kojem patentnom zahtjevu 1 do 5 se koristi u liječenju poremećaja koji je povezan sa CGRP, gdje je navedeni poremećaj migrenozna glavobolja, neurogena vazodilatacija, neurogena inflamacija, termalna povreda, cirkulacijski šok, crvenilo vezano za menopauzu, inflamatorne respiratorne bolesti ili kronična opstruktivna bolest pluća (HBOP).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603598P | 2012-02-27 | 2012-02-27 | |
| EP13708603.9A EP2820016B1 (en) | 2012-02-27 | 2013-02-25 | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
| PCT/US2013/027648 WO2013130402A1 (en) | 2012-02-27 | 2013-02-25 | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171620T1 true HRP20171620T1 (hr) | 2017-12-01 |
Family
ID=47844498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171620TT HRP20171620T1 (hr) | 2012-02-27 | 2013-02-25 | N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol |
| HRP20191655 HRP20191655T1 (hr) | 2012-02-27 | 2019-09-16 | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191655 HRP20191655T1 (hr) | 2012-02-27 | 2019-09-16 | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8759372B2 (hr) |
| EP (2) | EP2820016B1 (hr) |
| JP (2) | JP6208154B2 (hr) |
| KR (2) | KR102220969B1 (hr) |
| CN (1) | CN104136437B (hr) |
| AU (1) | AU2013226361B2 (hr) |
| BR (1) | BR112014021032B1 (hr) |
| CA (1) | CA2865585C (hr) |
| CY (2) | CY1119448T1 (hr) |
| DK (2) | DK3254681T3 (hr) |
| EA (1) | EA025358B1 (hr) |
| ES (2) | ES2642737T3 (hr) |
| HK (1) | HK1248111B (hr) |
| HR (2) | HRP20171620T1 (hr) |
| HU (2) | HUE034936T2 (hr) |
| IL (1) | IL234272B (hr) |
| LT (2) | LT3254681T (hr) |
| MX (1) | MX352171B (hr) |
| NO (1) | NO2935439T3 (hr) |
| PL (2) | PL3254681T3 (hr) |
| PT (2) | PT3254681T (hr) |
| RS (2) | RS56556B1 (hr) |
| SG (1) | SG11201404834XA (hr) |
| SI (2) | SI3254681T1 (hr) |
| SM (1) | SMT201700489T1 (hr) |
| WO (1) | WO2013130402A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013211929B2 (en) | 2012-01-26 | 2016-05-26 | Christopher J. Soares | Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use |
| SMT201700489T1 (it) * | 2012-02-27 | 2017-11-15 | Bristol Myers Squibb Co | N-(5s,6s,9r)-5-amm ino-6-(2,3-difluorofenil)-6,7,8,9-tetraidro-5h-cicloept a[b] piridin-9-il-4-(2-0ss0-2,3-diidro-ih-imidazo[4,5-b]piridin-i-il)piperidin-1-carbossilato, sale emisolfato |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| RU2764767C2 (ru) | 2015-03-06 | 2022-01-21 | Атеа Фармасьютикалс, Инк. | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ |
| IL265099B2 (en) * | 2016-09-02 | 2024-09-01 | Christopher J Soares | Pharmaceutical compositions comprising an effective amount of calcitonin gene-related peptide (cgrp) receptor antagonist or pharmaceutically acceptable salt thereof, for treating glaucoma |
| CN109689672B (zh) | 2016-09-07 | 2023-05-30 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
| SMT202500048T1 (it) * | 2017-02-01 | 2025-03-12 | Atea Pharmaceuticals Inc | Sale emi-solfato nucleotide per il trattamento di virus di epatite c |
| CN112153969A (zh) * | 2018-03-25 | 2020-12-29 | 拜尔哈文制药股份有限公司 | 用于cgrp相关障碍的瑞美吉泮 |
| TW202012001A (zh) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | C型肝炎病毒(hcv)感染硬化之患者的治療 |
| CN113316470A (zh) * | 2019-01-20 | 2021-08-27 | 拜尔哈文制药股份有限公司 | 用于治疗偏头痛突破的cgrp拮抗剂 |
| US20220249471A1 (en) * | 2019-06-14 | 2022-08-11 | The Regents Of The University Of California | New therapeutic approach to lung disease |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| JP2024509165A (ja) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | 片頭痛の治療及び／又は発生の低減 |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| AR126954A1 (es) * | 2021-09-02 | 2023-12-06 | Biohaven Pharm Holding Co Ltd | Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| CN116554164A (zh) * | 2022-01-27 | 2023-08-08 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
| WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
| WO2024180562A1 (en) * | 2023-03-02 | 2024-09-06 | Natco Pharma Limited | A process for the preparation of pure crystalline rimegepant and its salts thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA24500A1 (fr) * | 1997-03-21 | 1998-10-01 | Lg Life Sciences Ltd | Derive du sel d'acide carboxylique de naphthyridine . |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| JPWO2005085228A1 (ja) | 2004-03-05 | 2008-01-17 | 萬有製薬株式会社 | シクロアルカノピリジン誘導体 |
| JP4913061B2 (ja) | 2004-10-13 | 2012-04-11 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体拮抗薬 |
| EP1804919B1 (en) | 2004-10-22 | 2011-03-30 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
| AU2007238894A1 (en) | 2006-04-10 | 2007-10-25 | Merck Sharp & Dohme Corp. | Process for the preparation of pyridine heterocycle CGRP antagonist intermediate |
| DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| US8748429B2 (en) | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| SMT201700489T1 (it) * | 2012-02-27 | 2017-11-15 | Bristol Myers Squibb Co | N-(5s,6s,9r)-5-amm ino-6-(2,3-difluorofenil)-6,7,8,9-tetraidro-5h-cicloept a[b] piridin-9-il-4-(2-0ss0-2,3-diidro-ih-imidazo[4,5-b]piridin-i-il)piperidin-1-carbossilato, sale emisolfato |
-
2013
- 2013-02-25 SM SM20170489T patent/SMT201700489T1/it unknown
- 2013-02-25 CA CA2865585A patent/CA2865585C/en active Active
- 2013-02-25 PL PL17180587T patent/PL3254681T3/pl unknown
- 2013-02-25 SI SI201331560T patent/SI3254681T1/sl unknown
- 2013-02-25 SI SI201330759T patent/SI2820016T1/sl unknown
- 2013-02-25 US US13/775,528 patent/US8759372B2/en active Active
- 2013-02-25 ES ES13708603.9T patent/ES2642737T3/es active Active
- 2013-02-25 EP EP13708603.9A patent/EP2820016B1/en active Active
- 2013-02-25 SG SG11201404834XA patent/SG11201404834XA/en unknown
- 2013-02-25 WO PCT/US2013/027648 patent/WO2013130402A1/en active Application Filing
- 2013-02-25 DK DK17180587.2T patent/DK3254681T3/da active
- 2013-02-25 PT PT171805872T patent/PT3254681T/pt unknown
- 2013-02-25 BR BR112014021032-2A patent/BR112014021032B1/pt active IP Right Grant
- 2013-02-25 PT PT137086039T patent/PT2820016T/pt unknown
- 2013-02-25 PL PL13708603T patent/PL2820016T3/pl unknown
- 2013-02-25 MX MX2014009544A patent/MX352171B/es active IP Right Grant
- 2013-02-25 RS RS20171092A patent/RS56556B1/sr unknown
- 2013-02-25 KR KR1020207003401A patent/KR102220969B1/ko active Active
- 2013-02-25 KR KR1020147023856A patent/KR102076118B1/ko active Active
- 2013-02-25 AU AU2013226361A patent/AU2013226361B2/en active Active
- 2013-02-25 HU HUE13708603A patent/HUE034936T2/hu unknown
- 2013-02-25 HR HRP20171620TT patent/HRP20171620T1/hr unknown
- 2013-02-25 JP JP2014558927A patent/JP6208154B2/ja active Active
- 2013-02-25 LT LTEP17180587.2T patent/LT3254681T/lt unknown
- 2013-02-25 RS RSP20191191 patent/RS59295B1/sr unknown
- 2013-02-25 CN CN201380011305.6A patent/CN104136437B/zh active Active
- 2013-02-25 DK DK13708603.9T patent/DK2820016T3/da active
- 2013-02-25 LT LTEP13708603.9T patent/LT2820016T/lt unknown
- 2013-02-25 HU HUE17180587A patent/HUE047050T2/hu unknown
- 2013-02-25 EP EP17180587.2A patent/EP3254681B1/en active Active
- 2013-02-25 ES ES17180587T patent/ES2746031T3/es active Active
- 2013-02-25 EA EA201491585A patent/EA025358B1/ru not_active IP Right Cessation
- 2013-12-10 NO NO13811338A patent/NO2935439T3/no unknown
-
2014
- 2014-08-24 IL IL234272A patent/IL234272B/en active IP Right Grant
-
2017
- 2017-09-06 JP JP2017171358A patent/JP6476253B2/ja active Active
- 2017-10-10 CY CY20171101052T patent/CY1119448T1/el unknown
-
2018
- 2018-06-12 HK HK18107632.9A patent/HK1248111B/en unknown
-
2019
- 2019-09-11 CY CY20191100951T patent/CY1122121T1/el unknown
- 2019-09-16 HR HRP20191655 patent/HRP20191655T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171620T1 (hr) | N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol | |
| JP2014518286A5 (hr) | ||
| JP2012176975A5 (hr) | ||
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| AR108672A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| HK1210771A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| AU2023203088B2 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| TN2012000139A1 (en) | Cgrp receptor antagonists | |
| WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
| HRP20161742T4 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
| HRP20140814T1 (hr) | Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma | |
| ME02019B (me) | SPOJ IMIDAZ0[4,5-c]KINOLIN-2-0NA I NJEGOVA UPOTREBA KAO DVOJNOG INHIBITORA PI3 KINAZE I MTOR" | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| JP2016507502A5 (hr) | ||
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| HRP20192010T1 (hr) | Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja | |
| EA201690515A1 (ru) | Производные диазокарбазола в качестве пэт-лигандов белка tau | |
| EP4577550A1 (en) | Novel nlrp3 inflammasome inhibitors | |
| BRPI0816219B8 (pt) | compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso | |
| HRP20150030T1 (hr) | Derivati pirazolokinolina kao inhibitori dna-pk | |
| HRP20171773T1 (hr) | Kristalični oblik od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona i njegova uporaba kao antagonisti receptora oreksina | |
| HRP20171772T1 (hr) | Kristalični oblik soli od (s)-(2-(6-kloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona koji služi kao antagonist receptora oreksina | |
| WO2013042135A8 (en) | Heteroaryl compounds as 5-ht4 receptor ligands | |
| HRP20150356T1 (hr) | Kristalni oblici soli prasugrela |